Elranatamab Monotherapy
Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 33 patients (estimated)
- Sponsors
- University of California, San Diego
- Tags
- Bispecific T Cell Engager (BiTE), Bispecific Antibody, CD3, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2059
- NCT Identifier
- NCT06711705
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.